Loading
A phase 1/2 trial of Dostarlimab and Bevacizumab in advanced solid tumours, run by GlaxoSmithKline, now recruiting.
A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2) is a phase 1/2 interventional study registered as NCT06796907 by GlaxoSmithKline, with 305 participants planned, started 2025-03-04 and due to reach its primary completion in 2027-06-21. Interventions recorded: Mo-Rez, Dostarlimab and Bevacizumab.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares GSK, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Dostarlimab, GSK, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Dostarlimab, GSK and the tag pipeline.
Shares Dostarlimab, GSK and the tag pipeline.
Shares Dostarlimab, GSK and the tag pipeline.
Shares GSK, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Dostarlimab, GSK and the tag pipeline.
Shares Dostarlimab, GSK and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/